- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens acquires magnet maker
Oxford Magnet Technology will become a wholly owned subsidiary of Siemens Medical Systems late next year. Siemens, which holds a 51% stake in the British company, plans to purchase the remaining shares in a deal valued at $15.5 million, according to a
Oxford Magnet Technology will become a wholly owned subsidiary of Siemens Medical Systems late next year. Siemens, which holds a 51% stake in the British company, plans to purchase the remaining shares in a deal valued at $15.5 million, according to a Nov. 11 company announcement. Siemens will exercise its right to the buyout under a 1989 joint venture agreement with Oxford Instruments. The buyout is expected to occur when the initial 15-year term of the joint venture ends in September 2004. The transaction includes cash and the ongoing use by Oxford Instruments of certain intellectual property. It is subject to formal regulatory approval under German competition law. Oxford Magnet Technology was founded in 1982 to commercialize proprietary technology for MR magnets and accessories.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
